B

OSTON — The chemical arrived in September from a company in Ukraine, by way of a middleman in Portland, Maine. It was a whitish powder, and 10 grams — a bit more than two teaspoons’ worth — cost around $1,000.

That wasn’t bad for this business, and anyway, it was worth it. In 2015, this molecule had been shown to work against the single-cell parasite that causes visceral leishmaniasis, one form of a neglected tropical disease that kills an estimated 20,000 to 40,000 people a year. The chemical wasn’t perfect, though. It was unstable — so delicate that a hamster’s body broke it down before it could actually do its job.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy